3SOF

im thinking about taking a small position in stem...
im pretty interested what people think of all the stem stocks, which seems to be the best investment VIAC seems to be the only one with products on the market, gern i havent done any research on. stem and astm seem to have a long while before they get something on the market

I'd love to see it close above 3, that'll just look lovely on both the daily and weekly charts

I can dig it,higher the better

I rung the register this AM at 3.44 .....that's a good 52% gain...I'll probably jump back in later...hopefully around 3

"STEM" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                      
All history on a stock pick in 1 thread is awesome.                    
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.
Thank You....and good luck with all your trades....make some $$$     


Friday's closing chart....... "Happy New Year" !

 

Shorted STEM yesterday, I'm playing this one as a 'sell the news' type of trade.

It went up back so fast on the prospects of yesterday's house vote on the stem cell bill and its deemed for a good drop.

The bill was passed but not with the 2/3 majority vote needed to override Bush's impending veto.

Looking to cover between 2.90 and 2.80.

Just covered 2.84....took longer than I thought.

Wait for the next pullback for entry.
Like the risk/ reward

StemCells, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cell-based therapeutics to treat diseases of the central nervous system and liver.
18-Dec-08 07:30 ET In Play StemCells receives FDA approval to initiate clinical trial of HuCNS-SC cells in a Myelin Disease

20-Nov-08 08:16 ET In Play Transplant of windpipe grown from stem cells heralds new era in medicine - Daily Telegraph

12-Nov-08 09:12 ET In Play StemCells announces $20 mln in equity funding through sale of approx 13.8 mln shares at price of $1.45/share


52wk Range: 0.66 - 2.89
Volume: 23,890,861
Avg Vol (3m): 3,476,920

Technicals
Record Price High
Most Actives
Percentage Gainer

Last Price Quote is:
67.22%above 13-day MA
107.33%above 50-day MA
RS Rating: 98 

Fundamentals
Key Data:
Market Cap (M): $240.19 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Speculative Buy

just additional information:

Dawson James Securities Initiates Research Coverage of StemCells, Inc. With Buy Recommendation
Wednesday, January 14, 2009 07:30ET

PALO ALTO, Calif., Jan 14, 2009 (BUSINESS WIRE) -- StemCells, Inc. (NASDAQ:STEM) today announced that Dawson James Securities, Inc. has initiated research coverage on the Company with a "speculative buy" rating and a target price of $3.00 per share. The report was written by Stephen M. Dunn, Director of Research, who covers both public and private companies in the biotechnology, pharmaceutical and medical device sectors. The full report can be accessed on the Dawson James website, www.dawsonjames.com.

According to their website, Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology. Dawson James acted as co-lead placement agent in the Company's $20 million registered direct offering in November 2008.